FLT3 Tyrosine Kinase Inhibitors Synergize with BCL-2 Inhibition to Eliminate FLT3/ITD Acute Leukemia Cells through BIM Activation

Scientists investigated the combination of FLT3 tyrosine kinase inhibitors (TKIs) with other drugs, and found that the combination of a FLT3 TKI and a BCL-2i synergistically reduced cell proliferation and enhanced apoptosis/cell death in FLT3/ITD cell lines and primary acute myeloid leukemia samples.